Taxotere combination approved for induction therapy in SCCHN

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 10
Volume 16
Issue 10

FDA has approved Sanofi-Aventis' Taxotere (docetaxel) for use in combination with cisplatin and fluorouracil (TPF) for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

ROCKVILLE, Maryland—FDA has approved Sanofi-Aventis' Taxotere (docetaxel) for use in combination with cisplatin and fluorouracil (TPF) for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

FDA based its approval on TAX- 324, a multicenter, open-label, randomized trial of 501 patients. Overall survival was significantly prolonged with the Taxotere-containing regimen, compared with PF alone (P = .0058). Median survival was 70.6 months in the TPF group vs 30.1 months in the PF group (HR 0.70).

Articles in this issue
BRCA1 overexpression is strongly linked to poor outcome in NSCLC patients treated with cisplatin
Bill aims to 'revitalize' FDA by adding powers and databases
New myeloma trial results; two new studies initiated
Neoadjuvant trastuzumab increases pCR rates
Court rejects right of terminally ill to unproven drugs
Sorafenib improves overall survival in Asian HCC pts
Skipping tam doses increases risk of death
The SGR: The madness behind physician payment fee cuts
Dr. Pegram seeks new breast cancer challenges at Miami
SearchMedica.com receives award
FDA adds survival data to Erbitux product labeling
Colon ca chemo: Sequencing or upfront combinations?
FDA oks Campath as first-line Rx of B-CLL
Merck to donate 3 million doses of Gardasil to poor countries
Remembering Hopkins' Martin D. Abeloff, MD, scientist, educator, leader
Recent Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
Related Content
Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Ariana Pelosci
March 20th 2025
Article

Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Pembrolizumab/Bevacizumab Improves Efficacy in Nasopharyngeal Carcinoma

Pembrolizumab/Bevacizumab Improves Efficacy in Nasopharyngeal Carcinoma

Tim Cortese
March 2nd 2025
Article

Pembrolizumab and bevacizumab yielded an ORR of 58.3% vs 12.5% with pembrolizumab monotherapy in patients with platinum-resistant nasopharyngeal carcinoma.

Support for the supplemental biologics license application is based on phase 3 KEYNOTE-689 trial data.

Pembrolizumab Earns FDA Priority Review in Locally Advanced HNSCC

Roman Fabbricatore
February 25th 2025
Article

Support for the supplemental biologics license application is based on phase 3 KEYNOTE-689 trial data.

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

Petosemtamab Combo Earns Breakthrough Therapy Status in PD-L1+ HNSCC

Russ Conroy
February 20th 2025
Article

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

Cetuximab/Radiation Improves DFS in Locally Advanced SCCHN

Russ Conroy
February 1st 2025
Article

Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.